RTTNews) - Gilead Sciences Inc. (GILD) announced that phase 1 study data showed two different formulations of once-yearly lenacapavir, administered via intramuscular injection, achieved and maintained plasma concentrations exceeding those associated with HIV prevention efficacy...
.png)
3773 Howard Ave Las Vegas, NV
877-749-7128 ext. 500
Bruce.Oliver@REIPremiumCapitalLender.com
Copyright © 2023 privatemoneybroker. All Rights Reserved
